$125M Deal Awaits OK In Bristol-Myers Class Action
The lead plaintiff in a securities class action claiming Bristol-Myers Squibb Co. hid the terms of a deal it struck with a generics maker over the patent for its blood-thinning drug...To view the full article, register now.
Already a subscriber? Click here to view full article